Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmos has initiated the Phase 2a proof-of-concept trial of its compound levotofisopam (S-tofisopam) as a uric acid lowering agent in patients with hyperuricemia and gout at the Duke Clinical Research Unit of Duke University in the US.
Subscribe to our email newsletter
Levotofisopam, the S-entantiomer of the racemic mixture RS-tofisopam, is said to be a well tolerated, effective, nonsedating agent used to treat various disorders related to stress or autonomic instability.
The trial follows two Phase 1 clinical studies that were completed by Vela Pharmaceuticals in collaboration with Pharmos in October 2006.
The previous studies showed that levotofisopam treatment was generally well tolerated and was associated with a large and rapid reduction in serum uric acid values.
Pharmos, which owns the rights to both R- and S-tofisopam, the two enantiomers of racemic tofisopam, through two US issued composition-of-matter patents, plans to seek a partner to further develop levotofisopam for the treatment of gout after completion of this proof-of-concept clinical trial.